|
Home : Medical Devices : Gadolinium & Nephrogenic Systemic Fibrosis (NSF) : Newsfeeds : Biogen's Oral MS Drug Impresses Biogen's Oral MS Drug Impresses
Both doses of BG-12 met the secondary endpoints as well which included a statistically significant reduction in annualized relapse rate, the number of new or newly enlarging T2 hyperintense lesions, new gadolinium-enhancing (Gd+) lesions, and the rate of ...
Find a Gadolinium & Nephrogenic System Fibrosis (NSF) Lawyer Now
This form is secure and encrypted. More information about secure forms and your privacy here.
|




